Osteonecrosis Induced by Antiresorptive and Antiangiogenic Drugs in the Jaw

Abstract

ONMRM is a rare disease that attacks the soft and hard tissues of the oral cavity. The importance of this collection of information lies in providing a source of consultation necessary for the prevention, diagnosis, and treatment in the presence of Medication-Related Osteonecrosis in the Jaws (ONMRM). ONMRM treatments depend on various variables such as age, sex, comorbidities, disease status, ONJ stage, and symptoms. The protocol was considered in accordance with the Cochrane standards for systematic reviews. The search criteria complied with the Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols (PRISMA) guidelines. A total of 378 were reviewed and 68 studies were included in the review. Preventing ONJ should be a priority in patients receiving treatment with antiresorptive and antiangiogenic drugs, carefully considering oral hygiene with a prior review by a dentist and hygienist before starting therapy with these drugs. Although there is a lack of clarity concerning the functioning and interaction of antiresorptive and antiangiogenic drugs with the jaws, doubts arise about the pathophysiology of this condition as well as the course of ONJ.